Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients.
The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ?bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack.
Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors.
The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 20 | -5.07 Decreased by -225.00% | -0.56 Decreased by -805.36% |
| Aug 11, 20 | -0.96 Increased by +29.41% | -0.84 Decreased by -14.29% |
| May 11, 20 | -0.80 Increased by +48.72% | -1.23 Increased by +34.96% |
| Mar 26, 20 | 0.28 Increased by +124.14% | -1.14 Increased by +124.56% |
| Nov 12, 19 | -1.56 Decreased by -14.71% | -1.30 Decreased by -20.00% |
| Aug 12, 19 | -1.36 Decreased by -338.71% | -1.60 Increased by +15.00% |
| May 13, 19 | -1.56 Decreased by -136.36% | -1.33 Decreased by -17.29% |
| Mar 28, 19 | -1.16 | -1.41 Increased by +17.73% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 20 | 312.00 K Decreased by -69.41% | -49.98 M Decreased by -319.21% | Decreased by -16.02 K% Decreased by -1.27 K% |
| Jun 30, 20 | 528.00 K Decreased by -83.17% | -7.39 M Increased by +29.70% | Decreased by -1.40 K% Decreased by -317.82% |
| Mar 31, 20 | 7.03 M Increased by +130.30% | -6.09 M Increased by +47.87% | Decreased by -86.67% Increased by +77.37% |
| Dec 31, 19 | 15.29 M Increased by +301.79% | 2.30 M Increased by +126.69% | Increased by +15.02% Increased by +106.64% |
| Sep 30, 19 | 1.02 M Decreased by -50.07% | -11.92 M Decreased by -17.26% | Decreased by -1.17 K% Decreased by -134.86% |
| Jun 30, 19 | 3.14 M Increased by +88.36% | -10.52 M Decreased by -16.55% | Decreased by -335.12% Increased by +38.12% |
| Mar 31, 19 | 3.05 M Increased by +37.52% | -11.69 M Decreased by -73.59% | Decreased by -382.93% Decreased by -26.22% |
| Dec 31, 18 | 3.81 M Increased by +79.23% | -8.61 M Increased by +64.66% | Decreased by -226.18% Increased by +80.28% |